5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Caplin Point Laboratories Ltd.

•
caplinpoint.netBSE: 524742NSE: CAPLIPOINT
Market Cap₹ 20,939 Cr.
Current Price
High / Low₹ 2,877 / 1,500
Stock P/E31.5
Book Value₹ 483
Price to Book3.27
Dividend Yield0.29 %
ROCE25.0 %
ROE20.8 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 20.9% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 26.0%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 21.8%
  • Company has consistently been profitable over the last 5 years
  • Company has delivered good sales growth of 15.6% CAGR over last 5 years

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Though reporting repeated profits, the company pays out little dividend (9.5%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY 500NIFTY SMLCAP 250NIFTY MULTI MQ 50
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.CAPLIPOINT2754.7531.4720939.320.29179.0918.79610.3619.6324.9734.97
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
395410436453459483493502510534543600610
269273293308307318331334332345353396419
Operating Profit127137142145152165162168178189190204192
OPM %32.01%33.51%32.67%32.04%33.08%34.10%32.92%33.45%34.84%35.42%34.95%34.03%31.40%
12201717192131262330342834
Interest0000000000000
Depreciation11121416161716171618191922
Profit before Tax127146145146154169177177184201204213225
Tax %17.93%20.47%17.60%16.99%19.09%22.34%20.98%17.78%18.27%20.29%18.65%19.00%20.48%
Net Profit0000125131140145151160166173179
13.6215.1315.4416.0116.3217.2218.2818.7520.1020.3221.5622.3823.27

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
4025406498631,0611,2691,4671,6941,9372,1872,287
2773454176037378751,0261,1431,2911,4261,513
Operating Profit125195232260324395441551647761775
OPM %31.07%36.18%35.74%30.13%30.55%31.08%30.03%32.55%33.39%34.79%33.87%
101319412839576796116126
Interest11102111111
Depreciation1319233237474553667378
Profit before Tax121188227269314386451564677803844
Tax %21.04%23.22%22.18%20.18%19.83%20.05%16.48%18.25%20.05%19.07%19.62%
Net Profit96145177215251308377461541650678
EPS12.6519.1623.2328.2031.7139.2649.1860.1870.5784.37—
Dividend Payout %11.86%10.44%9.42%8.80%9.37%10.11%9.08%8.31%8.50%9.48%—

COMPOUNDED SALES GROWTH

10 Years:
25%
5 Years:
16%
3 Years:
14%

COMPOUNDED PROFIT GROWTH

10 Years:
30%
5 Years:
21%
3 Years:
19%

STOCK PRICE CAGR

10 Years:
27%
5 Years:
24%
3 Years:
42%
1 Year:
23%

RETURN ON EQUITY

10 Years:
31%
5 Years:
23%
3 Years:
22%
Last Year:
21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Sep 18

₹ 2

Rs.4.0000 per share(200%)Final Dividend

2026

May 29

₹ 2

Rs.4.0000 per share(200%)Interim Dividend

2025

Sep 12

₹ 1.50

Rs.3.0000 per share(150%)Final Dividend

2025

May 30

₹ 1.50

Rs.3.0000 per share(150%)Interim Dividend

2024

Sep 23

₹ 1.25

Rs.2.5000 per share(125%)Final Dividend

2024

May 31

₹ 1.25

Rs.2.5000 per share(125%)Interim Dividend

2023

Sep 14

₹ 1.25

Rs.2.5000 per share(125%)Final Dividend

2023

Jun 9

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2022

Sep 21

₹ 1

Rs.2.0000 per share(100%)Final Dividend

2022

May 23

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2021

Sep 20

₹ 0.75

Rs.1.5000 per share(75%)Final Dividend

2021

May 18

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2018

Sep 18

₹ 1

Rs.2.0000 per share(100%)Dividend

2017

Sep 7

₹ 0.75

Rs.1.5000 per share(75%)Dividend

2016

Sep 1

₹ 0.35

Rs.3.5000 per share(35%)Final Dividend

2016

Feb 15

₹ 0.25

Interim Dividend

2015

Oct 29

₹ 0.50

Rs.5.0000 per share(50%)Dividend

2020

Jun 18

₹ 0.20

Rs.0.4000 per share(20%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
15151515151515151515
Minority Interest0009182627313644
2103455758491,0811,3791,7752,2122,7413,478
16625111112121416
Trade Payables7994606488156153230218296
544086164151144196186182188
Total Liabilities3585007431,1261,3641,7302,1772,6863,2064,038
152169227273305287280453546580
Capital Work in Progress31510201415220117139209
174770611189281376590859
222837238179227288363336429
0000000543632826
Cash & Bank9379153223438463493553591621
70161246311416649615282370514
Total Assets3585007431,1261,3641,7302,1772,6863,2064,038

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
9110312699335418359318432523
Cash from Investing-36-69-100-55-29-377-218-320-335-582
Cash from Financing-7-129080-24-41-28-38-38-46
25-147370215-8126-4059-106

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
70.5670.5670.5670.5670.5670.5770.5770.5770.57
3.373.714.865.736.176.486.556.155.75
1.491.832.112.002.222.102.052.142.49
Government0.000.000.000.000.000.000.000.000.00
24.5723.9122.4721.7021.0520.8220.7921.1421.18

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04
Copy of Newspaper Publication

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04
Updates

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'.

2026-09-03
Updates

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.

2026-09-03
Shareholders meeting

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026

2026-09-02
Spurt in Volume

2026-09-02 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.

2026-09-02
Copy of Newspaper Publication

2026-09-02 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-01
Updates

2026-09-01 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA'.

2026-09-01
Spurt in Volume

2026-09-01 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-21
Updates

2026-08-21 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company s Subsidiary)'.

News

Recent coverage and analyst commentary for CAPLIPOINT

Loading news…

🤖

AI Stock Analyst

Caplin Point Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login